Among patients with recurrent or progressive, high-grade glioblastoma, treatment with the investigational Oncophage® (vitespen) cancer vaccine may improve survival. Preliminary results from a Phase II clinical trial were presented at the 2009 Joint Meeting of the Society for Neuro-Oncology (SNO) and the American Association of Neurological Surgeons (AANS)/CNS section on tumors.
Primary brain cancer is cancer that originates in the brain. Glioblastoma is one of the most common and fatal types of primary brain cancer. It develops from the glial cells, which are the most abundant cells in the nervous system. Glial cells provide supportive functions that facilitate the work of neurons (cells that transmit impulses between the brain, spinal column, and nerves).
Even with the most aggressive treatment available, many patients with glioblastoma will survive less than one year after diagnosis. As a result, researchers continue to evaluate new and innovative treatment strategies.
Oncophage is an investigational anticancer vaccine that is derived from the patient’s own tumor. The vaccine is intended to prompt the body’s immune system to respond to the cancer cells without affecting healthy cells.
The safety and efficacy of Oncophage for the treatment of recurrent or progressive, high-grade glioblastoma is being evaluated in a Phase II clinical trial. Although the study is ongoing, preliminary results were presented at the 2009 Joint Meeting of SNO and AANS/CNS.
- In the first 20 patients treated with Oncophage, median survival was 10.1 months. Thirty percent of patients have survived for one year or longer.
Although the Phase II trial is not complete, preliminary results suggest that Oncophage may be a promising treatment approach for patients with recurrent or progressive glioblastoma.
Reference: Antigenics Press Release. Data presented on Oncophage® cancer vaccine in recurrent glioma at SNO 2009. Available here. Accessed November 4, 2009.